Abstract
Objective. Neuropeptide S receptor 1 (NPSR1) is a G protein-coupled receptor involved in immune response and is associated with several inflammatory diseases. We investigated the possible contribution of several polymorphisms in the intronic region of NPSR1 to rheumatoid arthritis (RA).
Methods. Genotyping of 7 single-nucleotide polymorphisms (SNP) was performed in a total of 1232 patients with RA and 983 healthy controls of Spanish white origin by real-time polymerase chain reaction technology, using the TaqMan 5′-allele discrimination assay.
Results. One out of the 7 SNP analyzed (rs740347) was associated with RA [p after Bonferroni correction (pBNF) = 1.2 × 10−3, OR 0.73]. An association was also observed with rheumatoid factor-positive and shared epitope-positive RA (pBNF = 0.011, OR 0.73; pBNF = 0.037, OR 0.75, respectively).
Conclusion. Our results show that variations in the NPSR1 intronic region are associated with low risk in patients with RA, supporting other evidence that this locus represents a common genetic factor in inflammatory diseases.
- RHEUMATOID ARTHRITIS
- NPSR1
- RHEUMATOID FACTOR
- SHARED EPITOPE
- ANTICITRULLINATED PROTEIN ANTIBODIES
- SINGLE-NUCLEOTIDE POLYMORPHISM
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease, characterized by inflammation of synovial joints and pain affecting approximately 1% of the population worldwide. Both genetic and environmental factors seem to be involved in its complex etiology, although a strong genetic component has been described1,2.
Neuropeptide S receptor 1 (NPSR1), located in chromosome 7p, is a G-protein coupled receptor gene involved in leukocyte immune response3. Several studies have shown that NPSR1 expression is upregulated in inflammatory processes such as asthma, inflammatory bowel disease (IBD), and intestinal and cutaneous inflammatory diseases4,5,6, suggesting a main role of this gene in inflammation.
We analyzed 7 variations along the NPSR1 gene in RA patients and controls from Spain. Five of them (rs323917, rs323922, rs324377, rs324396, and rs740347) are located at the region between exons 2 and 3 of the NPSR1 gene and have been previously published as conferring genetic risk for diseases that present chronic inflammation including asthma4,7,8 and IBD5,9. Further, 2 additional single-nucleotide polymorphisms (SNP) (rs324987 and rs10263447) located in introns 3 and 4, respectively, were included in this study. Recently, these variations were reported to be associated with anticitrullinated protein antibody (ACPA)-negative RA and with disease activity in a Swedish population10.
MATERIALS AND METHODS
Patients
Our case-control study consisted of 1232 Spanish white patients with RA who met the American College of Rheumatology revised criteria for RA11 and 983 blood donors. All samples were matched by age and sex.
In our cohort 73.1% of the samples were characterized for rheumatoid factor (RF), 65.4% for shared epitope (SE), and 63.2% for ACPA. Of these patients, 67.6% were positive for RF, 65.4% encoded the SE, and 59.3% were seropositive for ACPA. All patients and controls were enrolled with local ethics committee approval and provided their informed consent.
NPSR1 SNP selection and genotyping
For genotyping, genomic DNA from patients and controls was isolated from peripheral white blood cells, using standard procedures. Seven SNP (dbSNP rs323917, rs323922, rs324377, rs324396, rs740347, rs324987, and rs10263447) localized in the NPSR1 gene were selected for investigation. Samples were genotyped using TaqMan® 5′ allelic discrimination Assay-By-Design method. The genotype call rate for every SNP was > 94.5% in controls and > 93.9% in patients.
Statistical analysis
All statistical analyses of the allele frequencies were carried out using the Linux software PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/). To test for association, 2 × 2 contingency tables and chi-square and/or Fisher’s exact tests, when appropriate, were used to calculate p values, OR, and 95% CI. Allelic combinations were analyzed using Haploview (V.4.2) and Unphased.
RESULTS
We performed single-point association analysis of 7 representative SNP, along the intronic region of NPSR1 (for details, see Appendix). All the SNP showed allele frequencies similar to those previously reported in European populations4,5. In a first step, we analyzed the possible implication of these SNP in RA susceptibility (Table 1, upper rows). We found an association for rs740347. The minor allele (C) was significantly decreased in RA patients compared to healthy controls [p after Bonferroni correction (pBNF) = 1.2E-03; OR 0.73].
To assess the possible implications of these 7 SNP for RA severity, we performed a stratification analysis for the presence of RF, SE alleles, and ACPA, when available (Table 1, lower rows). We found an association when comparing patients positive for RF or SE with controls for the NPSR1 rs740347: RF (pBNF = 0.011; OR 0.73), SE (pBNF = 0.037; OR 0.75). When we compared patients negative for RF, SE, or ACPA with controls, no association was observed for any of the 7 SNP (data not shown). Additionally, we compared RA patients positive for RF, SE, and ACPA with RA patients negative for each (Table 2). No association was detected for any of the analyzed SNP. This suggests that rs740347 is not associated with a clinical phenotype but with the global disease.
Table 3 shows allelic combination tests performed to analyze the possible interaction between the SNP of this genomic region. We found 3 different allelic combinations associated with RA susceptibility (CGCCGGC and CGCTGTG) or protection (CCACCGC).
DISCUSSION
NPSR1 gene seems to play a role in asthma7,8, IBD5,9, and RA10 in independent studies with ethnically different populations.
One of the 7 SNP analyzed in this study, rs740347, showed strong evidence of association with RA after correction for multiple comparisons. The rs740347 C allele conferred a protective effect on the global disease. On the other hand, the allelic combination analysis of NPSR1 variants suggests that the genomic region of this gene plays an important role in RA association.
The presence of positive RF, ACPA, and HLA-DRB1 alleles encoding a conserved sequence at amino acid positions 70–74, commonly known as the SE, has been associated with susceptibility and severity of RA12,13. We performed a stratification comparing patients with RA who were positive and negative for SE, RF, and ACPA with each other and with controls. We found an association for rs740347 comparing RF-and SE-positive patients with controls but not with RF-and SE-negative patients. It may be speculated that rs740347 is linked to the global disease and not to a subtype. The minor allele (C) of this SNP was previously seen to confer susceptibility to asthma in German and Italian populations7,14, but showed a low risk for susceptibility in a Colombian cohort15, similar to our results. Additionally, D’Amato, et al analyzed 19 NPSR1 polymorphisms in a RA cohort from Sweden10. However, none of the SNP analyzed showed association with the global disease. Population genetic variability between the 2 cohorts or interactions with other genes may be responsible for the lack of coincidence in the results. This group showed that rs324987 and rs10263447 were associated with ACPA-negative RA and disease activity. In our population these 2 SNP showed no evidence of association with the disease or with any of the subgroups analyzed.
Intronic position of the studied SNP suggests a possible involvement of associated polymorphism in regulation of splicing and protein isoform production. Variations in rs740347 may downregulate the function of NPSR1 in immunomodulation.
Our results provide evidence of involvement of NPSR1 in the genetic contribution for RA association in a Spanish population. Other replication studies and functional analyses are necessary to better elucidate its role in chronic inflammatory diseases.
Acknowledgment
The authors thank Sofía Vargas and Sonia Rodríguez (Instituto de Parasitología y Biomedicina López-Neyra, CSIC, Spain) for their excellent technical assistance; and all the patients and healthy controls for their essential collaboration.
Footnotes
-
Supported by a grant from RETICS Program, RD08/0075 (RIER), from Instituto de Salud Carlos III (ISCIII), Spain. Supported also in part by a European IMI BTCure Program grant.
- Accepted for publication March 7, 2012.